Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies

Vaccine

Volumn 27, Issue 23, 2009, Pages 3053-3062

  Le, Thuy T T ^a   Gardner, Joy ^a   Hoang Le, Diem ^a   Schmidt, Chris W ^a   MacDonald, Kelli P ^a   Lambley, Eleanore ^a   Schroder, Wayne A ^a   Ogbourne, Steven M ^b   Suhrbier, Andreas ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b Peplin Ltd   (Australia)

Author keywords

Cancer vaccines; Chemotherapy; Metastases

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; CANCER VACCINE; CD86 ANTIGEN; DENDRITIC CELL VACCINE; INGENOL 3 ANGELATE; PEP 005; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DRUG POTENTIATION; FEMALE; IMMUNOSTIMULATION; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CELL CULTURE TECHNIQUES; CHICKENS; COLONIC NEOPLASMS; DENDRITIC CELLS; DITERPENES; FEMALE; HUMANS; IMMUNIZATION; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; T-LYMPHOCYTES;

EID: 67349105944     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.025     Document Type: Article

References (52)

1. Ogbourne S.M., Hampson P., Lord J.M., Parsons P., De Witte P.A., and Suhrbier A. Proceedings of the first international conference on PEP005. Anticancer Drug 18 (2007) 357-362
2. Ogbourne S.M., Suhrbier A., Jones B., Cozzi S.J., Boyle G.M., Morris M., et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 64 (2004) 2833-2839
3. Challacombe J.M., Suhrbier A., Parsons P.G., Jones B., Hampson P., Kavanagh D., et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 177 (2006) 8123-8132
4. Cozzi S.J., Parsons P.G., Ogbourne S.M., Pedley J., and Boyle G.M. Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Res 66 (2006) 10083-10091
5. Kedei N., Lundberg D.J., Toth A., Welburn P., Garfield S.H., and Blumberg P.M. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res 64 (2004) 3243-3255
6. Anraku I., Harvey T.J., Linedale R., Gardner J., Harrich D., Suhrbier A., et al. Kunjin virus replicon vaccine vectors induce protective CD8 + T-cell immunity. J Virol 76 (2002) 3791-3799
7. Zeh III H.J., Perry-Lalley D., Dudley M.E., Rosenberg S.A., and Yang J.C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 162 (1999) 989-994
8. Nelson D.J., Mukherjee S., Bundell C., Fisher S., van Hagen D., and Robinson B. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. J Immunol 166 (2001) 5557-5566
9. Lenarczyk A., Le T.T., Drane D., Malliaros J., Pearse M., Hamilton R., et al. ISCOM based vaccines for cancer immunotherapy. Vaccine 22 (2004) 963-974
10. Shen Z., Reznikoff G., Dranoff G., and Rock K.L. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158 (1997) 2723-2730
11. Lou Y., Wang G., Lizee G., Kim G.J., Finkelstein S.E., Feng C., et al. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res 64 (2004) 6783-6790
12. Ali S.A., Lynam J., McLean C.S., Entwisle C., Loudon P., Rojas J.M., et al. Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity. J Immunol 168 (2002) 3512-3519
13. Elliott S.L., Pye S., Le T., Mateo L., Cox J., Macdonald L., et al. Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems. Vaccine 17 (1999) 2009-2019
14. Le T.T., Drane D., Malliaros J., Cox J.C., Rothel L., Pearse M., et al. Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. Vaccine 19 (2001) 4669-4675
15. MacDonald K.P., Rowe V., Filippich C., Thomas R., Clouston A.D., Welply J.K., et al. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation. Blood 101 (2003) 2033-2042
16. Machlenkin A., Goldberger O., Tirosh B., Paz A., Volovitz I., Bar-Haim E., et al. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity. Clin Cancer Res 11 (2005) 4955-4961
17. McAllister A., Arbetman A.E., Mandl S., Pena-Rossi C., and Andino R. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. J Virol 74 (2000) 9197-9205
18. Overwijk W.W., Theoret M.R., Finkelstein S.E., Surman D.R., de Jong L.A., Vyth-Dreese F.A., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8 + T cells. J Exp Med 198 (2003) 569-580
19. Mocellin S., Mandruzzato S., Bronte V., Lise M., and Nitti D. Part I: vaccines for solid tumours. Lancet Oncol 5 (2004) 681-689
20. Berinstein N. Overview of therapeutic vaccination approaches for cancer. Semin Oncol 30 (2003) 1-8
21. Mukherjee S., Nelson D., Loh S., van Bruggen I., Palmer L.J., Leong C., et al. The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene Ther 8 (2001) 580-588
22. Jager D., and Knuth A. Antibodies and vaccines-hope or illusion?. Breast 14 (2005) 631-635
23. Ni H.T., Spellman S.R., Jean W.C., Hall W.A., and Low W.C. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 51 (2001) 1-9
24. Huttner K.G., Breuer S.K., Paul P., Majdic O., Heitger A., and Felzmann T. Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells. Cancer Immunol Immunother 54 (2005) 67-77
25. Chianese-Bullock K.A., Pressley J., Garbee C., Hibbitts S., Murphy C., Yamshchikov G., et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 174 (2005) 3080-3086
26. McKinnon L.R., Ball T.B., Wachihi C., McLaren P.J., Waruk J.L., Mao X., et al. Epitope cross-reactivity frequently differs between central and effector memory HIV-specific CD8 + T cells. J Immunol 178 (2007) 3750-3756
27. Imai J., Hasegawa H., Maruya M., Koyasu S., and Yahara I. Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells. Int Immunol 17 (2005) 45-53
28. Creusot R.J., Thomsen L.L., van Wely C.A., Topley P., Tite J.P., and Chain B.M. Early commitment of adoptively transferred CD4 + T cells following particle-mediated DNA vaccination: implications for the study of immunomodulation. Vaccine 19 (2001) 1678-1687
29. Sheng K.C., Pouniotis D.S., Wright M.D., Tang C.K., Lazoura E., Pietersz G.A., et al. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 118 (2006) 372-383
30. Goldberg E.P., Hadba A.R., Almond B.A., and Marotta J.S. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery. J Pharm Pharmacol 54 (2002) 159-180
31. Crittenden M.R., Thanarajasingam U., Vile R.G., and Gough M.J. Intratumoral immunotherapy: using the tumour against itself. Immunology 114 (2005) 11-22
32. Yu P., Lee Y., Liu W., Chin R.K., Wang J., Wang Y., et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 5 (2004) 141-149
33. Hu J.C., Coffin R.S., Davis C.J., Graham N.J., Groves N., Guest P.J., et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12 (2006) 6737-6747
34. Casares N., Pequignot M.O., Tesniere A., Ghiringhelli F., Roux S., Chaput N., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202 (2005) 1691-1701
35. Luo L., Qiao H., Meng F., Dong X., Zhou B., Jiang H., et al. Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas. Int J Cancer 118 (2006) 1823-1830
36. Castano A.P., Mroz P., and Hamblin M.R. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 6 (2006) 535-545
37. Lake R.A., and Robinson B.W. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 5 (2005) 397-405
38. Terando A., and Mule J.J. On combining antineoplastic drugs with tumor vaccines. Cancer Immunol Immunother 52 (2003) 680-685
39. Saji H., Song W., Furumoto K., Kato H., and Engleman E.G. Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Clin Cancer Res 12 (2006) 2568-2574
40. Tanaka F., Yamaguchi H., Ohta M., Mashino K., Sonoda H., Sadanaga N., et al. Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. Int J Cancer 101 (2002) 265-269
41. Moron G., Dadaglio G., and Leclerc C. New tools for antigen delivery to the MHC class I pathway. Trends Immunol 25 (2004) 92-97
42. Kamstrup S., San Martin R., Doberti A., Grande H., and Dalsgaard K. Preparation and characterisation of quillaja saponin with less heterogeneity than Quil-A. Vaccine 18 (2000) 2244-2249
43. Fernando G.J., Stewart T.J., Tindle R.W., and Frazer I.H. Th2-type CD4 + cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. J Immunol 161 (1998) 2421-2427
44. Do Y., Hegde V.L., Nagarkatti P.S., and Nagarkatti M. Bryostatin-1 enhances the maturation and antigen-presenting ability of murine and human dendritic cells. Cancer Res 64 (2004) 6756-6765
45. Davis T.A., Saini A.A., Blair P.J., Levine B.L., Craighead N., Harlan D.M., et al. Phorbol esters induce differentiation of human CD34 + hemopoietic progenitors to dendritic cells: evidence for protein kinase C-mediated signaling. J Immunol 160 (1998) 3689-3697
46. Bennouna S., and Denkers E.Y. Microbial antigen triggers rapid mobilization of TNF-alpha to the surface of mouse neutrophils transforming them into inducers of high-level dendritic cell TNF-alpha production. J Immunol 174 (2005) 4845-4851
47. Maletto B.A., Ropolo A.S., Alignani D.O., Liscovsky M.V., Ranocchia R.P., Moron V.G., et al. Presence of neutrophil-bearing antigen in lymphoid organs of immune mice. Blood 108 (2006) 3094-3102
48. den Brok M.H., Sutmuller R.P., van der Voort R., Bennink E.J., Figdor C.G., Ruers T.J., et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 64 (2004) 4024-4029
49. den Brok M.H., Sutmuller R.P., Nierkens S., Bennink E.J., Frielink C., Toonen L.W., et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 95 (2006) 896-905
50. Seemann M.D. Whole-body PET/MRI: the future in oncological imaging. Technol Cancer Res Treat 4 (2005) 577-582
51. Blodgett T.M., Meltzer C.C., and Townsend D.W. PET/CT: form and function. Radiology 242 (2007) 360-385
52. Ellis R.J., and Kaminsky D.A. Fused radioimmunoscintigraphy for treatment planning. Rev Urol 8 Suppl 1 (2006) S11-S19